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Abstract: Hypertension is a complex condition in which various actors and mechanisms combine,
resulting in cardiovascular and cerebrovascular complications that today represent the most fre-
quent causes of mortality, morbidity, disability, and health expenses worldwide. In the last decades,
there has been an exceptional amount of experimental, epidemiological, and clinical studies confirm-
ing a close relationship between magnesium deficit and high blood pressure. Multiple mechanisms
may help to explain the bulk of evidence supporting a protective effect of magnesium against hy-
pertension and its complications. Hypertension increases sharply with advancing age, hence older
persons are those most affected by its negative consequences. They are also more frequently at
risk of magnesium deficiency by multiple mechanisms, which may, at least in part, explain the
higher frequency of hypertension and its long-term complications. The evidence for a favorable
effect of magnesium on hypertension risk emphasizes the importance of broadly encouraging the
intake of foods such as vegetables, nuts, whole cereals and legumes, optimal dietary sources of
magnesium, avoiding processed food, which are very poor in magnesium and other fundamental
nutrients, in order to prevent hypertension. In some cases, when diet is not enough to maintain an
adequate magnesium status, magnesium supplementation may be of benefit and has been shown to
be well tolerated.
Keywords: magnesium; hypertension; aging; ions; insulin resistance; cardiovascular disease;
diet; supplement
1. Introduction
Magnesium is the most present divalent intracellular cation in the human body,
and the second intracellular ion after potassium. This primary cation has been traditionally
considered as cofactor of about 300 regulatory enzymes [1], but current databases list over
600 enzymes for which magnesium is cofactor [2]. Magnesium is involved in fundamental
cellular reactions comprising ATP-dependent biochemical processes as part of the activated
MgATP complex, DNA synthesis, RNA expression, muscular and neural cell signaling,
glucose metabolism, and blood pressure control [3,4].
Although magnesium was first recommended as treatment for malignant hyperten-
sion as early as 1925 [5], subsequent studies failed to demonstrate reliable results. In 1983,
a study by Resnick et al. [6], showed a close inverse relationship of serum ionized magne-
sium and plasma renin activity. The following year (1984) Resnick and Gupta, using novel
31P-NMR technique that allowed precise assessment of intracellular cytosolic magnesium
concentrations, published a seminal paper showing that persons with essential hyperten-
sion had consistently lower levels of intracellular magnesium with an inverse relationship
between these concentrations and blood pressure values, the lower intracellular magne-
sium, the higher blood pressure [7]. This close quantitative relationship confirmed the
presence of a powerful link between magnesium deficiency and human essential hyperten-
sion. Afterwards, a number of experimental, clinical, and epidemiological studies exploring
the relationship of this key cation with hypertension have been undertaken. Magnesium
is involved in blood pressure regulation by diverse mechanisms including modulation of
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vascular tone and reactivity acting as a calcium antagonist [8,9], the renin–angiotensin–
aldosterone system (RAAS) [6], endothelial function [10–12], vascular remodeling and
stiffness [13], and catecholamine release [14]. Magnesium deficiency has been also related
to low-grade inflammation, oxidative stress [12,15,16], insulin resistance, and metabolic
syndrome [3].
High blood pressure is the strongest independent and modifiable risk factor for heart
failure, ischemic heart disease, cerebrovascular events, chronic kidney disease, and cog-
nitive decline worldwide [17]. Hypertension was associated with 4.9, 2.0, and 1.5 million
deaths due to ischemic heart disease, hemorrhagic stroke, and ischemic stroke, respectively,
in 2015 [18]. According to the World Health Organization, 1.13 billion adults have hyper-
tension currently [19]. The prevalence of hypertension rises remarkably with advancing
age and due to the continuous and global increase in aging populations, the prevalence
of hypertension and its derived detrimental consequences are still increasing [20]. Hence,
public health preventive actions are urgently needed, comprising nutrition, to combat the
hypertension pandemic.
A number of investigations have assessed the association of dietary and supplemental
magnesium with the development of high blood pressure and meta-analyses on cohort
studies and RCTs have confirmed protective effects [21–24]. A recent summary of meta-
analyses on the effects of electrolytes on hypertension revealed that the greatest beneficial
effect on blood pressure lowering was ascribed to magnesium intake followed by potassium
intake and by salt reduction [25]. Dietary magnesium intake is deficient in a large propor-
tion of European and US populations where Western dietary patterns full of processed
food are very frequent [26–29]. Indeed, magnesium is abundant in green leafy vegetables,
nuts, legumes, and whole cereals, while it is practically absent in processed food and sugar
sweetened beverages [30]. Chronic inadequate magnesium intake, particularly frequent in
old age, has been associated with an increased risk of multiple clinical conditions including
hypertension and stroke [3,8,31]. The Dietary Guidelines for Americans recommend a daily
intake of 420 mg of magnesium for men and 320 mg for women [32], but estimates indicate
that more than 60% of Americans are under the recommendation [28].
Most studies have shown inverse associations of dietary magnesium intake with
hypertension [33–35] or risk of incident hypertension [36–40], while fewer studies have
reported negative or inconclusive results [41–43]. A systematic review and meta-analysis
of cohort studies reported that a 100 mg/day increment of magnesium dietary intake
was significantly associated with 5% reduction in incident hypertension [21]. Three meta-
analyses of 11, 34, and 28 RCTs found that supplementation with oral magnesium resulted
in significant reductions in blood pressure vs. controls [22,23,44]. Earlier meta-analyses
suggested benefit with less prominent effect, possibly due to heterogeneity and to the
inclusion of persons with and without other chronic diseases in the analyses [24,45].
The present article aims to review the role of alterations of magnesium metabolism
in the pathophysiology of high blood pressure, condition which is particularly frequent
in old age. We discuss the possible mechanisms involved and the available evidence of
the effects of dietary and supplemental magnesium on blood pressure lowering and risk
of hypertension.
2. Magnesium Metabolism, Dietary Sources, and Requirements
Approximately 24 g (1 mole) of magnesium are present in the human body, of which
almost 2/3 stored in the bone and 1/3 in the cellular compartment. Blood serum contains
less than 1% of the total body magnesium with normal concentrations ranging between
0.75 and 0.95 mmol/L (1.7–2.5 mg/dL or 1.5–1.9 meq/L). Magnesium concentrations in the
serum are extremely constant and are tightly controlled and kept within this narrow range
by the kidney and small intestine increasing their fractional magnesium absorption during
magnesium deprivation. If the lack of magnesium persists, bone stores help maintaining
serum magnesium concentration through exchange with extracellular fluid [3].
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Serum magnesium exists in three forms: 25% is bound to albumin and 8% bound to
globulins (protein-bound fraction); 12% corresponds to the chelated fraction; while 55% rep-
resents the metabolically active ionized fraction. Hypomagnesemia is generally identified
as a serum magnesium concentration below 0.75 mmol/L [3]. Magnesium is an intracellu-
lar regulator of the cell cycle physiology and apoptosis; its intracellular concentrations are
as well highly regulated. Most intracellular magnesium exists in bound form. Circulating
magnesium concentrations do not always correspond to intracellular or total magnesium.
Magnesium equilibrium depends on magnesium intake, its absorption through intestine
(mainly small intestine), its renal excretion, and its requirements in all tissues [46]. Magne-
sium’s requirement per day in healthy adults is estimated at 300–400 mg (5 to 6 mg/kg/day)
but in several physiological conditions this requirement may be increased (i.e., exercise,
aging, pregnancy, etc.), as well as in some pathological conditions (diabetes, infections, etc.).
Because magnesium stored in bone tissue cannot be quickly exchanged with magnesium in
the extracellular fluids, the rapid magnesium needs are provided by magnesium stored in
the intracellular compartment. About 120 mg of magnesium are eliminated into the urine
every day contributing substantially to magnesium homeostasis [47]. Renal magnesium ex-
changes are closely dependent on magnesium body status, because magnesium depletion
increases magnesium reabsorption. Thus, urinary excretion is reduced in magnesium-
depleted conditions [48]. Diuretic, drugs that are commonly used in hypertension and
heart failure, may as well modify renal magnesium exchanges by reducing the reabsorption
of magnesium [49]. No known hormonal factor is specifically involved as a main regulator
of magnesium homeostasis. Nevertheless, several hormones have been shown to exert
actions on magnesium balance and transport, including parathyroid hormone, calcitonin,
catecholamines, and insulin [3,50].
Table 1 depicts some food sources of magnesium, which correspond to foods belong-
ing to dietary patterns generally considered healthy. Contrariwise, the foods contained
in the Western diet, most of them ultra-processed, are very poor in magnesium. Ultra-
processed food, according to NOVA classification, the most widely used classification
of processed food, is defined as the “formulations of food substances often modified by
chemical processes and then assembled into ready-to-consume hyper-palatable food and
drink products using flavors, colors, emulsifiers and other cosmetic additives” [51]. In the
last decades, the global supply of food products derived from industrial processes has
increased substantially. The percentage of energy intake derived from ultra-processed
foods has been reported to be 29.1% in France [52], 42% in Australia [53] and 57.9% in the
USA [54]. Parallel to this transition towards diets based on processed food, a remarkable
increase of non-communicable diseases, including obesity and hypertension, has been
reported worldwide [55]. There is growing evidence linking consumption of this type
of foods with poor diet quality, increased cardiovascular risk factors (e.g., hypertension,
dyslipidemia), and harmful health outcomes such as obesity, metabolic syndrome [51]
and also with increased mortality risk [52,56,57]. Negative nutritional characteristics of
ultra-processed foods include its high content of low-quality fat, added salt and sugar,
as well as low vitamin, mineral and fiber content [51].
Regarding the actual dietary sources of magnesium, in the USA, where 57.9% of en-
ergy intake comes from ultra-processed food [54], a study analyzing data from the National
Health and Nutrition Examination Survey (NHANES) 2003 to 2008 among 25,351 partici-
pants, found that minimally processed food contributed only 27.6% to total magnesium
intake, whereas ready-to-eat foods and packaged ready-to-eat foods contributed 28.8%
and 26.3% to dietary magnesium intake, respectively [58]. This corresponds with the low
consumption of foods rich in magnesium reported by the Dietary Guidelines for Americans
(estimated % of persons below recommendation across all ages and both sexes in the USA
was near 100% for whole grains, near 90% for total vegetables, over 80% for beans and peas,
and near 60% for nuts, according to data from NHANES 2007–2010), which also indicated
that 49% of the USA population, considering all age-groups, had a magnesium intake
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below the estimated average requirement [32]. Other estimates indicated that over 60% of
Americans are under the recommended daily intake [28].
Table 1. Some Food Sources of Magnesium.
Food Serving Magnesium (mg)
Cereal all bran 1/2 cup 112
Cereal oat bran 1/2 cup dry 96
Brown rice, medium-grain, cooked 1 cup 86
Fish, mackerel, cooked 3 ounces 82
Spinach, frozen, chopped, cooked 1/2 cup 78
Almonds 1 ounce (23 almonds) 77
Swiss chard, chopped, cooked 1/2 cup 75
Lima beans, large, cooked 1/2 cup 63
Cereal, shredded wheat 2 biscuits 61
Peanuts 1 ounce 48
Molasses, blackstrap 1 tablespoon 48
Hazelnuts 1 ounce (21 hazelnuts) 46
Walnuts 1 ounce (14 walnuts) 44
Okra, frozen, cooked 1/2 cup 37
Milk, 1% fat 8 fluid ounces 34
Banana 1 medium 32
Data from the European Prospective Investigation into Cancer and Nutrition (EPIC) study
reported that in Nordic and central European countries (i.e., Germany, UK, the Netherlands,
Denmark, Sweden, and Norway), a large proportion (76 to 79%) of magnesium intake
comes from highly processed foods. In Southern European countries, (i.e., Italy, Spain,
and Greece) a lower proportion of magnesium intake derives from highly processed foods
(43 to 67%), which is lower than in Nordic and central European countries, but still high [59].
Because highly processed foods are in general poor in magnesium, this may mean that
people, both from the USA and European countries, consume large amounts of this type of
foods to obtain magnesium, which is in any case insufficient, as indicated by the finding of
frequent dietary magnesium deficiency at the population level [26–29].
The main sources of dietary magnesium, some examples shown in Table 1, contain
also other components known to have beneficial health effects, i.e., other minerals and
micronutrients, vitamins, fiber, and phytochemicals with recognized antioxidant and anti-
inflammatory actions. Therefore, magnesium intake may be a marker of adherence to a
healthy diet at a population level. Analyses of data from the Seguimiento Universidad de
Navarra (SUN) prospective project showed that a higher adherence to the Mediterranean
dietary pattern was associated with a lower prevalence of inadequacy for the intake of
vitamins and minerals, including magnesium. Conversely, participants with a higher adher-
ence to the Western dietary pattern (with greater consumption of red and processed meat,
eggs, sauces, precooked food, fast-food, energy soft drinks, sweets, whole dairy and pota-
toes) were less likely to achieve adequate intakes of vitamins and minerals, including
magnesium. Participants in the fifth quintile of adherence to Western dietary pattern had a
2.5-fold increased risk for having more than ten nutrient intake recommendations unmet,
comprising magnesium, when compared to the first quintile of adherence to Western
dietary pattern [60].
3. Mechanistic Insights on the Relationship of Magnesium and Hypertension
Several mechanisms can help explain the connection between magnesium and high
blood pressure, including its calcium antagonist actions and its effects on endothelial
function, vascular tone, reactivity, vascular cells growth, vascular calcification, oxidative
stress and chronic inflammation, and glucose metabolism, as will be discussed in the below
subsections (Table 2).
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Table 2. Main Mechanisms of Magnesium-related Blood Pressure Regulation.







• Oxidative stress and inflammation
RASS: Renin-Angiotensin-Aldosterone System.
3.1. Regulation of Vascular Tone and Contraction
Magnesium is a major physiological regulator of vascular tone, and modulates periph-
eral vascular resistance by enhancing relaxation responses and mitigating agonist-induced
vasoconstriction. The effects of magnesium as a modulator of vascular tone are also
connected to its competitive action with calcium, while other mechanisms may be also
involved as discussed below.
3.1.1. Magnesium as a Calcium Antagonist
Calcium ion plays a crucial role in the control of vascular smooth muscle cells exci-
tation, contraction and impulse propagation. All modifications of the endogenous mag-
nesium status determine changes in vascular tone and, consequently, variations in blood
pressure [4,8]. Although magnesium is not directly involved in the contraction process,
it plays a role in blood pressure regulation through modulation of vascular smooth muscle
tone and contractility by controlling calcium ion concentrations and availability [61,62].
Thus, a reduction of magnesium levels raises smooth muscle calcium content; while on the
contrary, an increase of magnesium concentrations reciprocally lowers calcium content in
the cells [63,64]. Extracellular magnesium levels and cellular-free magnesium concentra-
tions modulate vascular smooth muscle cells tone by voltage-dependent L-type calcium
channels [64]. Furthermore, magnesium can itself function as a natural physiologic cal-
cium channel blocker [65], modulating the activity of the calcium-channels [66]. Thus,
magnesium counteracts calcium and functions as physiological calcium blocker, similarly
to synthetic calcium antagonists [67].
Magnesium binds hydration water more than calcium. Hence, the hydrated magne-
sium, with a radius of about four hundred times larger than its radius after dehydration,
is more challenging to dehydrate. This dissimilarity clarifies many of magnesium biological
properties, including its calcium antagonistic actions, in spite of similar chemical charge
and reactivity of both ions. As such, it is almost impossible for magnesium to pass through
narrow channels in biological membranes, opposite to calcium, because of its hydration
cover [68].
Two mechanisms are proposed for the extracellular magnesium-inhibition of calcium
current in vascular smooth muscle cells. On one hand, extracellular magnesium would
stabilize the excitable membranes and raise the excitation threshold which diminishes the
current via the voltage-gated calcium channels by neutralizing the negative charges on
the external surface of the cell membrane. On the other hand, it has been suggested that
extracellular magnesium may reduce calcium current by directly binding to the calcium
channels. Magnesium may either cause an allosteric modulation of the channel gating,
or mechanically block the channel pore, thus causing its closure [69].
In vascular smooth muscle cells, the concentration of intracellular magnesium mod-
ulates their tone by means of its effects on ion channels and calcium signal transduction
pathways. As mentioned, decreased extracellular magnesium activates calcium influx,
while raised extracellular magnesium levels inhibit calcium influx through calcium chan-
nels [64]. Variations in intracellular magnesium modulates channels activity by altering its
amplitude, activation/inactivation kinetics, and by factors such as phosphorylation, thus re-
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ducing calcium entry. The magnesium-related activation of the calcium-ATPase pump in
the sarcoplasmic/endoplasmic reticulum sequesters intracellular calcium into the sarcoplas-
mic reticulum. Elevated intracellular magnesium stimulates inositol-1,4,5-trisphosphate
(IP3) breakdown, inhibits IP3-induced calcium release from the sarcoplasmic reticulum,
and competes with intracellular calcium for cytoplasmic and reticular binding sites [69].
Contrariwise, low concentrations of intracellular magnesium stimulate IP3-mediated mobi-
lization of calcium from the sarcoplasmic reticulum and reduce calcium-ATPase activity,
reducing calcium efflux and reuptake by the sarcoplasmic reticulum. This causes an ac-
cumulation of cytosolic calcium and a raised cellular calcium concentration, which is a
crucial factor for vasoconstriction [64]. Magnesium can also block sarcoplasmic reticulum
calcium release through the ryanodine receptor [70]. The action of magnesium to compete
with calcium for binding sites on troponin C also modulates the activity of contractile
proteins and their dynamics [71]. In addition, intracellular magnesium regulates vascular
smooth muscle cells G-protein-coupled activity of various receptors, including those for
angiotensin II (type 1), endothelin-1, vasopressin, and norepinephrine and epinephrine,
as well as intracellular calcium signal transduction pathways, such as translocation of
phospholipase C and activation of protein kinase C [69].
Considering all those previously described direct and indirect actions of magnesium
on the vascular smooth muscle cells, it is plausible to propose a role of magnesium de-
ficiency in the pathophysiology of alterations of blood pressure homeostasis, such as
hypertension. Thus, elevation of blood pressure and vascular hyperreactivity can be in-
duced in experimental models by diminishing magnesium both in the in vitro environment,
or depleting magnesium in experimental animals [72].
3.1.2. Magnesium and Endothelial Function
Magnesium stimulates vascular endothelial functions by affecting the release of nitric
oxide, endothelin-1, and prostacyclin [73]. Magnesium ions directly trigger the produc-
tion of prostacyclin and nitric oxide [74,75] and its concentrations were found inversely
related to endothelin-1 in hypertension experimental models [76], further supporting the
ability of magnesium to modulate vasodilatation. Magnesium deficit have been shown
to potentiate endothelial dysfunction by means of the activation of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB), a well-known transcription mediator
of proinflammatory pathways [77], Low concentrations of extracellular magnesium re-
duces endothelial cell proliferation, stimulates monocytes adhesion, and impairs vasoactive
molecules, such as nitric oxide and prostacycline [78]. Another key mediator of magne-
sium’s effects on the endothelium is interleukin (IL)-1alpha, regulated by NF-kB, which in
turn may be an inducer of NF-kB. IL-1alpha increases sharply in a low magnesium content
environment and induces the production of various chemokines and adhesion molecules
in vascular endothelial cells by activating NF-kB, hence, provoking adhesion, aggregation,
and diapedesis of monocytes. Reduced magnesium concentrations trigger the secretion of
IL-8 and chemokines overexpressed in human atherosclerotic plaques, promoting mono-
cyte adhesion and chemotaxis to endothelial cells. IL-8 also stimulates proliferation and
migration of vascular smooth muscle cells. The secretion of IL-1alpha induced by low
serum magnesium stimulates overexpression of vascular cell adhesion molecule (VCAM)-1
on the surface of endothelial cells, which contributes to leukocyte migration. Granulocyte-
macrophage colony-stimulating factor is also significantly higher in endothelial cells with
magnesium deficit [78].
Supporting the key role of magnesium on endothelial function, oral magnesium
supplementation was significantly associated with improvement in exercise tolerance and
brachial artery endothelial function, in patients with coronary artery disease [11]. Likewise,
oral magnesium improved endothelial function in type 2 diabetic older adults evaluated
by non-invasive flow-mediated dilatation of the brachial artery [10]. A recent systematic
review and meta-analysis summarized the effects of oral magnesium supplementation
on vascular function in RCTs. Even if available studies were scarce and heterogeneity
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was high among the studies included, in subgroup analyses oral magnesium significantly
improved flow-mediated dilation in studies longer than 6 months, including unhealthy
persons, older than 50 years, or with BMI higher than 25 kg/m2 [79].
3.1.3. Magnesium and the Renin-Angiotensin-Aldosterone System (RAAS)
In 1983, a study by Resnick et al. evaluated the relationship between plasma renin
activity and serum concentrations of ionized calcium and magnesium in normotensive
and hypertensive patients clustered into low-renin, normal-renin, and high-renin groups.
Overall, the range of plasma renin activity in hypertensive participants showed a con-
tinuous and close inverse relation with serum ionized magnesium concentrations and a
positive relation with serum ionized calcium [6]. The authors concluded that plasma renin
activity may reflect modifications in calcium and magnesium fluxes across cell membranes
in hypertension.
In experimental models, it has been shown that magnesium has some direct effects
on the synthesis of aldosterone and indirect effects through the RAAS [80]. Aldosterone
secretion is a calcium-dependent process, which can be affected by magnesium due to
its calcium antagonist properties mentioned above. Rats maintained in a magnesium-
deficient diet exhibited a slight reduction of the thickness of the inner zones and an
increment of the juxtaglomerular granulation index and width of the zona glomerulosa
of the adrenal cortex. When magnesium was restored in the diet, the thickness of the
zona glomerulosa returned to normal [81]. Infusion of magnesium in humans decreased
the production of aldosterone induced by angiotensin II, and on the contrary, dietary-
induced magnesium deficiency enhanced angiotensin-induced aldosterone synthesis [82].
Magnesium supplementation has been shown to improve the pressor effects of angiotensin
II and stimulate the production of vasodilator prostacyclin [74,75].
3.1.4. Magnesium and Catecholamines
The release of catecholamines from the adrenal gland and from adrenergic nerve
terminals in response to sympathetic stimulation is a calcium-mediated process. As dis-
cussed above, magnesium competes with calcium for membrane channels, blocking the
calcium entrance, and consequently modifying these calcium-linked responses. The ability
of magnesium to prevent the release of catecholamines from both the adrenal gland and
peripheral adrenergic nerve terminals was shown in earlier laboratory experiments [83].
Based on these effects, magnesium sulfate was used with benefit in patients with phaeochro-
mocytoma undergoing surgery in order to help control cardiovascular changes at induction
and tracheal intubation during anesthesia [84]. Subsequent cases confirmed the beneficial
effects of magnesium sulfate on life-threatening pheochromocytoma crisis with hyperten-
sive encephalopathy and catecholamine-induced cardiomyopathy [85]. Also in patients
undergoing anesthesia for other reasons, pretreatment with magnesium sulfate attenuated
the systolic blood pressure upsurge and the rise in norepinephrine and epinephrine after
tracheal intubation [86]. Magnesium is needed for the catalytic action of adenylate cyclase.
As such, in the absence of magnesium the decreased activity of adenylate cyclase leads to
an increased secretion of acetylcholine from preganglionic nerves, which in turn triggers
further release of catecholamines from the adrenal glands [87].
Experimental animals fed with a magnesium-deficient diet showed a significant rise
in catecholamines excretion [88]. Also in an experimental model of hypertension, it has
been reported that magnesium has important sympatholytic effects by blocking N-type
calcium channels at nerve endings, inhibiting norepinephrine release, and decreasing
blood pressure independently of its direct vasodilating actions [89]. These effects are very
relevant considering that sympathetic stimulation plays a pivotal role in the regulation of
arterial blood pressure [83]. A recent systematic review and meta-analysis evaluating the
effectiveness of intravenous magnesium sulfate on the hemodynamic fluctuations associ-
ated with the creation of pneumoperitoneum in adults undergoing laparoscopic surgery
showed a consistent reduction in the magnesium treated groups compared to placebo in
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heart rate, systolic, diastolic and mean blood pressures, at 5 min, 10 to 15 min, and 30 min
after pneumoperitoneum, confirming its ability to blunt the physiologic sympathetic re-
sponse associated with exposure to injurious stimuli [90].
3.1.5. Magnesium and Vascular Calcification
Vascular calcification refers to the deposit of calcium in the arterial wall and is closely
linked to high blood pressure. Hypertension is a risk factor for atherosclerosis and intimal
calcification. Nevertheless, not all vascular calcifications take place with atherosclerosis,
while calcification of the vessel media is associated with reduced elasticity and arterial
stiffness, a major cause of isolated systolic hypertension particularly frequent in old age.
Notably, vascular calcification, independent of its anatomical site, is itself a risk factor for
cardiovascular mortality [91]. Some studies have indicated a protective effect of magne-
sium against vascular calcification, attributable to its calcium antagonistic effects including
hydroxyapatite formation and calcium transport into the cells [92,93]. The possible mech-
anism to explain such protective effect has not been yet fully clarified. In experimental
models, it has been reported that calcium deposition in the rat aortic wall dramatically
increased when the magnesium concentration was increased considering also calcium
concentration (ratio of magnesium:calcium = 1:1) compared to low magnesium concen-
tration and high calcium concentration (ratio magnesium:calcium = 1:3), suggesting that
the impact of magnesium on vascular calcification might be studied in association with
calcium levels [9].
In primary human aortic vascular smooth muscle cells, increasing magnesium concen-
trations improved cell viability and normalized the release of proteins involved in vascular
calcification [94]. In this in vitro experimental model, the formation of calcium–phosphate–
apatite crystals assessed with a qualitative analysis suggested a potential beneficial effect of
magnesium in reducing the number and intensities of crystal formation. The authors sug-
gested that their results seem to exclude a physicochemical role of magnesium in altering
crystal growth, composition or structure, but that this attenuating effect should be linked to
an active cellular role [67]. Also in bovine vascular smooth muscle cells higher magnesium
concentrations prevented calcification and inhibited the expression of osteogenic proteins,
apoptosis and further progression of already established calcification [95]. One of the
intracellular mechanisms identified as possible mediator of magnesium’s anti-calcifying
effect is the inhibition of the Wnt/beta-catenin signaling pathway [96].
In community-dwelling participants of the Framingham Heart Study without any car-
diovascular disease at baseline, self-reported dietary and supplemental magnesium intake
was inversely associated with coronary and abdominal artery calcification [97], supporting
a protective role of magnesium on vascular calcification and derived complications, such as
isolated systolic hypertension, stroke and coronary heart disease events.
3.2. Magnesium, Insulin Action, Diabetes, and Cardiometabolic Syndrome
Hypertension is common among patients with diabetes, and it is a strong risk factor for
atherosclerotic cardio-vascular disease, heart failure, and microvascular complications in
diabetic patients [98]. A recent analysis of the tendency of diabetics to develop hypertension
and of hypertensives to develop diabetes concluded that the development of diabetes and
hypertension track each other over time and that a reduced insulin sensitivity is a common
feature of both pre-diabetes and pre-hypertension and an index of progression to the two
conditions [99]. The constellation of risk factors known as metabolic syndrome including
hypertension, obesity, and impaired glucose tolerance/insulin resistance has compelling
evidence of its association with magnesium deficiency [3,39,50,100–104]. Cardiometabolic
syndrome represents a strong risk factor for cardiovascular events and for the progression
to type 2 diabetes. There is also convincing evidence of the link between magnesium
deficit and diabetes. Type 2 diabetes has been associated with both intracellular and
extracellular magnesium depletion, mostly in patients with poorly controlled glycemic
profiles, longer duration of the disease, and in those with macro- and microvascular chronic
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complications [50,105–107]. Reduction in intracellular and/or ionized plasma magnesium
has been reported in diabetic patients with normal values of total magnesium [108–110].
One of the key mechanisms that may induce magnesium depletion in diabetes is a low
dietary magnesium intake and an increase in magnesium urinary loss, while absorption and
retention of dietary magnesium appears to be unmodified in these patients [111]. A diet de-
ficient in magnesium, very common in western dietary patterns full of ultra-processed food,
has been associated with an impaired cellular insulin-mediated glucose uptake and with a
remarkably high risk of developing glucose intolerance and type 2 diabetes [50]. On the
other hand, magnesium depletion in diabetic patients has been related to renal calcium and
magnesium wasting. It has been suggested that both, hyperglycemia and hyperinsulinemia,
may play a role in the increased urinary magnesium excretion contributing to magnesium
reduction. Urinary magnesium excretion rates were more than doubled in diabetic patients
during hyperglycemia, in parallel with a reduction in plasma magnesium [112]. An ef-
fective metabolic control is associated with a reduced urinary magnesium wasting [107].
In addition, hyperinsulinemia, associated with insulin resistant conditions, may contribute
per se to the urinary magnesium depletion, while reduced insulin sensitivity may itself
affect magnesium transport [113]. In this way, lower magnesium levels may not only be a
consequence, but may also predispose to the development of diabetes. Insulin resistance
reduces renal magnesium reabsorption leading to urinary magnesium wasting. Thus,
persons with type 2 diabetes may end up in a vicious circle in which hypomagnesemia
causes insulin resistance and insulin resistance reinforces magnesium depletion [50,105].
After the introduction of insulin-containing extracts from animal pancreas as a life-
saving therapy for diabetes in the early 1920s [114], a study published in 1933 reported
increased blood magnesium and sodium concentrations during therapy with impure in-
sulin extracts [115]. Only 30 years later in 1960 when synthetic insulin was available and
methods of magnesium measurements improved, it became apparent that insulin regulates
magnesium renal reabsorption [116]. Afterwards, microperfusion experiments in mouse
thick ascending limb of Henle loop showed an increased magnesium permeability after
addition of insulin [117]. Furthermore, insulin stimulated magnesium uptake in mouse
distal convoluted tubule cells [118]. It seems then clear that magnesium transport is a key
molecular target to help explain the actions of insulin in the kidney.
In the last decades there have been advances in the study of magnesium transport
systems, but the results of the available studies are still inconsistent. For example, in 2012,
transient receptor potential melastatin type 6 (TRPM6) was identified as the molecular
target of insulin signaling and some mutations in TRPM6 were proposed as responsible
for rendering the channel insensitive to insulin stimulation in patch clamp analyses [119].
This was not confirmed when higher amounts of magnesium intake were examined to-
gether with possible genetic variations. Analyses of fifteen studies from the CHARGE
(Cohorts for Heart and Aging Research in Genomic Epidemiology) Consortium providing
data from 52,684 participants showed that magnesium intake was significantly and in-
versely associated with fasting glucose and insulin, after adjustment for age, sex, energy in-
take, body mass index, and behavioral risk factors. No magnesium-related SNP (single
nucleotide polymorphism) or interaction between any SNP and magnesium reached signif-
icance after correction for multiple testing [120]. Also in experimental models, the mRNA
expression of TRPM6 in diabetic rats, are contradictory with some reports showing in-
creased TRPM6 expression [121], and others showing downregulation of TRPM6 [122].
These inconsistencies, as in other animal studies, may depend on the different experi-
mental model used. Moreover, because hypomagnesemia may per se stimulate TRPM6
expression [123], it is difficult to isolate the effects of hypomagnesemia from those of
diabetes itself.
Another transport system involved in the renal actions of insulin is the thiazide-
sensitive Na-Cl cotransporter in the distal convoluted tubule [124–127]. Insulin stimulation
of this system has been shown to increase sodium reabsorption by activating an intra-
cellular signaling cascade that includes mTOR complex 2 and stress-activated protein
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kinase/oxidative stress responsive kinase to increase Na-Cl cotransporter phosphorylation
and activity [124,126,127]. It is noteworthy that, as mentioned above, all phosphoryla-
tion reactions are magnesium dependent. It has been suggested that hyperinsulinemia in
patients with diabetes may cause an increased activation of Na-Cl cotransporter, hence,
of renal sodium reabsorption, contributing to hypertension that is so common in type
2 diabetic patients [98]. This assumption is backed by studies in Zucker obese rats and
db/db mice showing hypertension, hyperinsulinemia, and increased Na-Cl cotransporter
activity [125,126].
In epidemiological studies magnesium deficit has been linked to an increased risk
of glucose intolerance, type 2 diabetes and cardio-metabolic syndrome [39,100,128].
Depletion of intracellular magnesium inducing an altered activity of the tyrosine kinase
insulin receptor, as well as all other magnesium-dependent kinases of the insulin signaling,
impairs insulin sensitivity and may contribute to the development of clinical conditions
associated with a reduced insulin sensitivity, such as glucose intolerance, type 2 diabetes
and hypertension. Additional mechanisms proposed to explain the link of magnesium with
insulin resistance/metabolic syndrome are inflammation and oxidative stress. In general,
conditions commonly associated with magnesium deficiency, such as diabetes and aging,
are also associated with increased free radical formation and derived damage to cellular
processes [50,129]. The view that a dietary magnesium deficit may cause and/or exacer-
bate insulin resistance is confirmed by data, both in experimental animals [130] and in
humans [82], showing that a diet poor in magnesium is associated with insulin resistance.
A magnesium-deficient diet caused a significant impairment of insulin-mediated glucose
uptake in sheep [131], while magnesium supplementation delayed the development of
diabetes in a rat model of diabetes [132]. A higher intake of magnesium was related to
lower fasting insulin concentrations among non-diabetic women [133], and a significant
inverse association was present between total dietary magnesium intake and the insulin
responses to an oral glucose tolerance test [134]. Because of this reported increased risk for
developing glucose intolerance and type 2 diabetes in persons with dietary magnesium
deficits, it has been proposed a potential benefit of dietary magnesium supplementation,
as a preventive tool in persons with diabetes or at risk for developing type 2 diabetes.
However, the number of studies concerning magnesium supplementation in people with
or at risk of diabetes is still limited [135]. Benefits of Mg supplementation on glucose
control improvements have been suggested in most, but not all, studies. A systematic
review and meta-analysis from our group including eighteen double-blind randomized
controlled trials (RCTs), twelve in people with diabetes and six in people at high risk of
diabetes, showed that magnesium supplementation appears to have a beneficial effect im-
proving glucose parameters in persons with diabetes and also improving insulin-sensitivity
parameters in those at high risk of diabetes [136].
3.3. Magnesium, Oxidative Stress and Chronic Inflammation
The etiology of hypertension involves the complex interaction among various ele-
ments, including genetic, environmental, anatomic, adaptive, neural, endocrine, humoral,
and hemodynamic factors, first described by Irvine Page in his mosaic theory [137].
Since then, with the enormous progress in hypertension research it has become apparent
that common molecular and cellular events in various organs lie beneath many features
of the original mosaic theory. In 2013, David Harrison highlighted oxidative stress and
inflammation as major drivers harmonizing diverse cellular events and organ systems
involvement in hypertension, revisiting Page’s theory. Harrison proposed that oxidative
stress and inflammation increase neuronal firing in specific brain centers, increase sym-
pathetic outflow, alter vascular tone and morphology, and cause sodium retention in the
kidney together with other cellular signals, including calcium signaling and endoplasmic
reticulum stress [138]. The crucial role of inflammation in cardiovascular and metabolic
disease was first proposed by Ross in the 1990s, showing that excessive inflammatory-
fibroproliferative responses to various forms of injury to arterial endothelium and smooth
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muscle are soundly involved in atherogenesis [139]. Nowadays, there is compelling experi-
mental and clinical evidence indicating that hypertension is associated with inflammation,
fibrosis, and activation of immune cells, processes that are driven in large part by oxida-
tive stress [140]. Expression of vascular cell adhesion molecules (VCAMs), production of
inflammatory mediators (e.g., tumor necrosis factor [TNF], IL-1, IL-6, 1L-17), stimulation
of proinflammatory signaling pathways (e.g., mitogen-activated protein kinase [MAPK],
signal transducer and activator of transcription [STAT]), activation of transcription factors
(e.g., NF-kB, STAT activator protein 1, hypoxia-inducible factor 1), and circulating levels of
inflammatory biomarkers (e.g., C-reactive protein [CRP], plasminogen activator inhibitor
[PAI]-1, ILs) are all increased in hypertension [141–143]. Although it still remains unclear
whether inflammation is a cause or an effect of hypertension, it is clear that the immune
system and oxidative stress are important players.
Along with all the above-mentioned actions on key mediators of hypertension, it has
been convincingly shown that low blood concentrations of magnesium are associated
with an increased production of oxygen free radicals also known as reactive oxygen
species (ROS). Also diets with poor magnesium content have been linked to a low-grade
chronic inflammatory state, mainly by two mechanisms: first, by initiating an excessive
production and release of IL-1beta and TNF-alfa, and second, by triggering the synthesis of
nitric oxide and of some inflammatory markers [144,145]. Magnesium deficiency increases
platelet aggregation and adhesiveness, and inhibits growth and migration of endothelial
cell, potentially altering microvascular functions [145].
Several studies in experimental models have shown that magnesium deficiency
causes: (i) elevation of proinflammatory molecules TNF-alfa, IL-1-beta, IL-6, VCAM-1,
and PAI-1 [145,146]; (ii) increased circulating inflammatory cells [147]; and (iii) increased
hepatic production and release of acute phase proteins (i.e., complement, alfa2-macroglobulin,
fibrinogen) [145,148]. As mentioned above, endothelial dysfunction associated with low
magnesium exposure has been linked to the release of inflammatory mediators [149].
In humans, clinical data have demonstrated that reduced serum magnesium levels as
well as low dietary magnesium intakes are strongly associated with low-grade systemic
inflammation [12,28,150]. Other studies have shown an inverse relationship of dietary
magnesium intake and serum magnesium with inflammation markers. The Women’s
Health Study has shown that magnesium dietary intake was inversely related to systemic
inflammation, measured by serum CRP concentrations, as well as with the prevalence of the
metabolic syndrome in adult women [103]. Magnesium intake was inversely longitudinally
related to incident diabetes in a large population of American adults, at least in part
explained by the inverse association of magnesium intake with systemic inflammation
and insulin resistance [151]. In addition, using the 1999–2002 NHANES databases, it was
found that magnesium intake was inversely associated with CRP levels. Among 70% of the
population studied, not taking magnesium supplements, dietary magnesium intake below
the RDA was significantly related to an increased risk of having elevated CRP [28]. A recent
investigation confirmed the significantly inverse relationship of low dietary magnesium
intake with serum hs-CRP concentrations in a large Finish population [152].
Magnesium deficits have also been associated with decreased antioxidant defense
competence and increased oxidative stress. There is evidence showing that magnesium
depletion may cause an increased production of oxygen-derived free radicals in different
tissues, decreased antioxidant enzyme expression and activity, decreased cellular and tissue
antioxidant levels, increased production of superoxide anion by inflammatory cells and
increased oxygen peroxide production and increased oxidative tissue damage [145,153].
Low serum magnesium (i.e., extracellular) can trigger magnesium transporters such
as TRPM7 and solute carrier family 41 A1 (SLC41A1), a mammalian magnesium car-
rier [154], inducing magnesium efflux from cells to increase serum magnesium concentra-
tions. This may decrease intracellular magnesium altering magnesium- and ATP-dependent
cellular signaling functions. A decreased intracellular magnesium may trigger magnesium
stores in the mitochondria to release magnesium [155] through SLC41A3 [156]. Reduced mi-
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tochondrial magnesium content may further compromise magnesium- and ATP-associated
mitochondrial signaling and functions. This may explain the mitochondrial overproduction
of ROS and decreased ATP observed in magnesium deficient mice [157,158]. Recently,
it has been shown that magnesium deficiency in diabetic mice increased mitochondrial
oxidative stress and contributed to cardiac diastolic dysfunction, which was reversed
by magnesium supplementation [157]. Thus, magnesium can act as a mitochondrial
antioxidant. Magnesium deficiency has been shown to alter mitochondrial function by
several mechanisms, including alterations in coupled respiration [159–161], increasing
mitochondrial ROS production [157,158,162], suppressing the antioxidant defense system
(e.g., superoxide dismutase, glutathione, catalase, vitamin E) [163–166], inducing calcium
overload via the mitochondrial calcium uniporter [157,167,168], attenuating pro-survival
signaling [169–171], and promoting opening of mitochondrial ATP-sensitive potassium
channel [172], inner membrane anion channel [173], and mitochondrial permeability tran-
sition pore [174]. These effects result in depolarization of the mitochondrial membrane
potential [167]. Conversely, magnesium repletion has been shown to improve mitochon-
drial function by suppression of mitochondrial ROS overproduction [157,158], inhibition
of mitochondrial permeability transition pore opening and cytochrome C release [175–177],
preservation of mitochondrial membrane potential [178,179], reduction of mitochondrial
calcium accumulation [180–182], increase of protein expression of the anti-apoptotic B-cell
lymphoma 2 (Bcl-2) family and concurrently decreasing pro-apoptotic protein expression
such as Bcl-2-associated X protein [169,179], decrease of apoptosis by suppressing activa-
tion of hypoxia-inducible factor 1alpha and p38 mitogenactivated protein kinase/c-Jun
N-terminal kinase (p38/JNK) signaling [179], and by downregulation of autophagy [182].
We have previously proposed a link between the action of magnesium to alter the
antioxidant capacity and to increase oxidative stress, inflammation, and lipid oxidation
with the possible development of insulin resistance, type 2 diabetes, hypertension and
cardio-metabolic syndrome [50]. Aging, very frequently associated with cardiovascular
disease including hypertension, as well as with other chronic diseases, is characterized by
a chronic, low-grade inflammatory state that involves several tissues and organs, and that
has been named “inflammaging” [183]. Our group has suggested a link between the
magnesium deficit through its role in causing a pro-oxidant –pro-inflammatory state to
several age-related diseases and the low-grade inflammation associated with aging [15,129].
Magnesium itself has antioxidant properties scavenging oxygen radicals possibly by af-
fecting the rate of spontaneous dismutation of the superoxide ion [184] and all the other
mechanisms described above.
4. Hypertension in Old Age and Magnesium Deficit—Two Frequent
Coexisting Conditions
Aging is accompanied by significant hemodynamic changes, leading to an ever-
growing pandemic of hypertension. Modifications in central arterial structures are char-
acterized initially by a decline in aortic distensibility with an increased diastolic blood
pressure, followed by a sharp increase in pulse wave velocity (PWV), pulse pressure (PP)
and systolic blood pressure, beyond the sixth decade. These trajectories of PWV and PP
differ with advancing age. In addition, there is an increased prevalence of salt-sensitive hy-
pertension in old age [185]. Epidemiological data from the Framingham Study suggest that
the lifetime risk of incident hypertension is over 90% for a person aged 55 to 65 years [186].
Arterial stiffness is the major cause of elevated systolic blood pressure and PP (systolic
minus diastolic blood pressure) as well as lower diastolic blood pressure in older adults.
These age-related vascular alterations are powerful determinants of major cardiovascular
disease events and all-cause mortality [187–191]. Vascular aging entails modifications in the
properties of all the elements of the vascular wall, including endothelium, vascular smooth
muscle, and extracellular matrix, leading to vascular stiffness and possible elevation of
systolic blood pressure. These age-related arterial changes and those associated with hy-
pertension (and with diabetes and atherosclerosis) are strictly connected at the cellular and
molecular levels [192]. In the young adult, arterial vessels adapt blood flow and pressure
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during cardiac systole to facilitate perfusion to tissues during diastole. This is largely
determined by elasticity, distensibility, and compliance of the arterial wall. Increased
stiffness and loss of elasticity need greater force to accommodate blood flow, leading to
increased systolic blood pressure and consequent increased cardiac work load. Various
interrelating factors at the systemic (blood pressure, hemodynamics), vascular (vascular
contraction/dilatation, extracellular matrix remodeling), cellular (cytoskeletal organization
and inflammatory responses in endothelial cells and vascular smooth muscle), and molecu-
lar (oxidative stress, intracellular signaling, and mechanotransduction) levels contribute to
arterial stiffness in hypertension [187–189]. Modifications in magnesium status and cellular
content play a key role in many of these processes as discussed in previous subsections.
Hence, interventions focused on correcting magnesium deficiency and maintaining an
optimal magnesium balance may prove to be an appropriate strategy against arterial aging
due to its positive effects on various mediators of the vascular aging process.
In experimental models, the effects of magnesium deficit and supplementation on
the mechanical properties of common carotid artery were assessed continuously with
an echo-tracking device. Histological examination showed a larger cross-sectional area,
increased intima-media thickness and a greater media:lumen value in carotid artery of
magnesium-deficient rats, suggesting growth and/or proliferation of arterial wall com-
ponents in this condition. A negative linear relationship between intima-media thickness
and plasma magnesium concentration was reported [193]. Another experimental study
compared young and old rats with long-term magnesium-deficient diet vs. magnesium-
supplemented diet. Old rats fed a normal diet (not deficient or supplemented) showed
increased PP, increased aortic wall thickness, loss of endothelium-dependent relaxation,
and a decrease of the aortic wall elastin/collagen ratio. Long-term magnesium deficiency
progressively increased systolic blood pressure and intra-arterial PP. Histological exami-
nation showed that magnesium deficiency increased the age-induced deleterious effects
on composition and structure of aorta (media thickness, increased collagen content and
reduction in the elastin/collagen ratio), which led to large artery rigidity [194]. In humans,
aortic distensibility measured with MRI imaging in the descending thoracic and abdominal
aorta in relation to 31P-MR spectroscopic measurement of in situ intracellular free magne-
sium levels in brain and skeletal muscle showed that aortic distensibility in hypertensive
patients was consistently and significantly reduced as was brain and muscle intracellular
magnesium, while systolic blood pressure was inversely related to aortic distensibility [13].
Another frequent characteristic of hypertension associated with aging is sodium sensitiv-
ity [195]. It has been shown that the ability of a high salt diet to elevate blood pressure is
related to intracellular free magnesium in humans [196].
Along with the higher prevalence of hypertension, especially systolic due to arterial
stiffness, aging is frequently associated with magnesium deficiency [129]. The total body
and intracellular magnesium content tend to decrease with age. Aging is often associ-
ated with magnesium deficiency due to reduce intake and/or absorption, increased renal
wasting and/or reduced tubular reabsorption, as well as age-related diseases and their
treatment with certain pharmacological therapies [129]. In general, total plasma magne-
sium concentrations do not change with age [197]. Variability in magnesium circulating
concentrations is generally associated with the presence of age-related diseases and mod-
ifications in renal function. An increased magnesium retention rate has been shown in
old age, suggesting a significant subclinical magnesium deficit, not detected by the usual
measurements of total serum magnesium [198]. We observed a decline in intracellular free
magnesium with age; specifically, we studied the trend of intracellular magnesium content
with age, using the gold standard method (31P-NMR spectroscopy) in healthy young and
older persons and observed a continuous age-dependent fall of intracellular magnesium
levels in red blood cells of healthy older adults [199], while total serum magnesium was not
modified in the different age groups. Many older adults are susceptible to chronic latent
magnesium deficiency and epidemiological data from the US and Europe have confirmed
that low magnesium intake is very common [26–29,200], in societies in which it is usual
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that processed and ultra-processed foods are the basis of the diet [51,53,54]. This type of
dietary pattern is very poor in components of high nutritional value, that is, essential macro
and micronutrients including magnesium [30].
Malnutrition is a common geriatric syndrome, frequently connected to frailty [201,202],
particularly in very old persons. A multicenter study from Ireland showed that 63% of
persons aged over 70 years were malnourished or at risk for malnutrition [203]. Another
multicenter study including 4500 older adults from twelve European countries in diverse
geriatric settings reported that two-thirds of participants were at risk of malnutrition or
malnourished [204]. Numerous factors contribute to malnutrition in old age including
decreased appetite due to reduced sense of smell and taste, poor oral health, loss of
vision and hearing, and depression-associated anorexia; decreased ability to purchase
and prepare food, altered energy need, decreased physical activity and sarcopenia, loss of
self-sufficiency, isolation, and financial limited access to food [201]. All these factors may
certainly result in poor diets lacking essential nutrients including magnesium. A former
study showed that magnesium intake in older persons was near half of recommended
dietary allowance (RDA) [205]. Other studies confirmed the fact that older populations
have low dietary intake of magnesium [206–208]. Perhaps older adults are more likely to
experience low magnesium intake for the reasons described above, but indeed, this is a
problem in the whole population regardless of age [209]. The RDA of magnesium in the
US is 420 mg/day for men and 320 mg/day for women, requirement that do not seem to
change with age [210], but the mean intake of magnesium in the US older population is far
below this recommendation (225 and 166 mg/day for men and women, respectively) [26].
Sixty-eight per cent of US adult population has been shown to consume less than the RDA
of magnesium, 45% consume less than 75% of the RDA, and 19% consume less than 50% of
the RDA [28]. The “Suppléments en Vitamines et Minéraux AntioXydants” (SU.VI.MAX)
French study showed that 77% of women and 72% of men had dietary magnesium intakes
lower than RDA; and 23% of women and 18% of men consumed less than two thirds of the
RDA [200]. The problem of dietary magnesium deficiency is even worse in nursing home
residents [211–217].
Data from the NHANES III showed that magnesium intake tend to decrease with
age [26]. Additionally, older people who suffer from chronic diseases and who use multiple
medications have a higher risk of magnesium deficiency [15]. Decreased intestinal mag-
nesium absorption may further contribute to its deficiency in old age [218]. Magnesium
absorption occurs mainly in the duodenum and ileum by both passive and active trans-
port. Alterations of magnesium intestinal absorption in old age may be worsen by the
common age-related impaired vitamin D homeostasis [29]. Latent primary renal disorders
frequent in older adults may also be associated with an increased magnesium loss linked
to a reduced renal tubular reabsorption.
Secondary magnesium deficiencies may be associated with the use of multiple medica-
ments, known as polypharmacotherapy (i.e., loop diuretics, thiazides, proton pump in-
hibitors, cytotoxic drugs, digoxin, aminoglycosides, steroids), or with some pathological
conditions (e.g., type 2 diabetes, insulin resistance, alcoholism, hyperadrenoglucocorticism,
HIV/AIDS, acute myocardial infarction, stroke, etc.). One of the most frequently used
drugs in the cure of hypertension are diuretics, which by increasing magnesium urinary
loss can be a frequent cause of hypomagnesemia [219]. It has been reported the finding
of hypomagnesemia in 38% to 42% of hypokalemic patients. The correction of potassium
and/or calcium deficits may be difficult to achieve unless the magnesium deficit is also
corrected, hence in patients with hypokalemia and/or hypocalcemia, a magnesium defi-
ciency should be considered [220]. Unfortunately, there are no readily and easy methods
to accurately assess magnesium status. The serum magnesium (only 1% of total body
magnesium) is easily available but may not adequately reflect body magnesium stores
which are mostly intracellular. Normal circulating concentrations may be found even if
intracellular magnesium is depleted because intracellular stores are recruited to keep serum
concentrations within normal range [3,110]. Therefore, as no fully accurate and robust
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method to measure magnesium status is available, the biochemical measurements should
always be supported by a clinical assessment of patients at risk for magnesium deficiency
in order to timely star a proper therapy.
Many other medications may reduce magnesium absorption and/or diminish mag-
nesium circulating concentrations (e.g., proton pump inhibitors, antacids, H2 block-
ers, antibiotics, antivirals, antiepileptic drugs, and antihistamines, among others) [220].
Hypomagnesemia can become severe when different factors are combined, such as those
described in a case report of posterior reversible encephalopathy syndrome (PRES) with as-
sociated hypertension, and reversal of symptoms after normalization of magnesium blood
levels by magnesium administration and suspension of a proton pump inhibitor [221].
Western diets are generally very low in green vegetables and whole grains (as those
examples in Table 1), and rich in refined foods, and are often severely deficient in mag-
nesium. Most of the magnesium present in processed food is lost in refining procedures,
and thus, diets that provide a high proportion of daily calorie requirements from refined
or processed foods are likely to be low in magnesium [222]. Magnesium deficiency in
plants is becoming an increasingly severe problem linked to the development of industrial
agriculture [223]. Moreover, some pesticide agents, commonly used in the crops, such as
glyphosate, may chelate minerals including magnesium [224] further decreasing the content
of magnesium in soil and in some crops. Organic food, from pesticide-free soils, has been re-
ported to have significantly more magnesium than non-organic control food [225]. Table 3
summarizes the mechanisms of magnesium deficiency in old age.
Table 3. Main Mechanisms of Magnesium Deficit with Aging.
• Primary magnesium deficit:
# Inadequate magnesium dietary intake
# Reduced efficiency of magnesium absorption (associated with reduced vitamin
D levels)?
# Increased urinary excretion of magnesium (associated with age-dependent reduction
of kidney function and of magnesium tubular reabsorption)
• Secondary magnesium deficiency:
# Associated with age-related diseases and comorbidities
# Increased urinary magnesium loss secondary to drugs (i.e., diuretics) frequently
used in hypertensive older adults
5. Methods
We searched, from database inception to 16 December 2020, in Pubmed the topics
of magnesium and hypertension using the following search for including all the studies
(observational or interventional) eligible: “hypertension” [tiab] AND “magnesium” [tiab]
Filters: Meta-Analysis, Observational Study, Randomized Controlled Trial, Systematic
Review. A similar search was made in Scopus. Altogether, 200 title/abstracts were eligible
from Pubmed and 627 from Scopus. After removing the duplicates, 758 title/abstracts were
retrieved for a total of 40 works potentially eligible. Finally, a total of 18 eligible studies
were considered for this narrative review (Figure 1 and Table 4).
Papers were considered eligible if: a. they included magnesium as treatment in
placebo-controlled RCTs or if they assessed circulating or dietary magnesium in cohort
studies, including meta-analyses of these works; b. they investigated hypertension as
main condition in RCTs or as outcome in cohort studies. Concomitant supplementations
(e.g., vitamin D), not clear definition of age or hypertension or cross-sectional/case–control
design/no randomized controlled trials, studies made in children/adolescents/pregnant
women were reasons of exclusion.










Figure 1. PRISMA flow-chart for the search and study selection.
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Table 4. Summary of results from prospective studies and meta-analyses of trials and cohort studies on the association of magnesium and hypertension included in the review.
Authors/Country Year














USA [36] 1989 - 58,218/3275
Prospective
cohort - 4 years
For women with high intakes of magnesium vs. low intakes,
the RR of hypertension was 0.65 (95% CI, 0.53–0.80).
Ascherio et al.
USA [38] 1992 - 30,681/1248
Prospective
cohort - 4 years
Among male health professionals, dietary magnesium was
significantly associated with lower risk of hypertension after
adjustment for age, relative weight, alcohol consumption,
and energy intake.
Ascherio et al.
USA [37] 1996 - 41,541/2526
Prospective
cohort - 4 years
Among women who did not report hypertension during
follow-up, magnesium was significantly inversely associated with
self-reported systolic and diastolic BP, after adjusting for age, BMI,
alcohol consumption, and energy intake. Dietary magnesium was
not significantly associated with risk of hypertension,
after adjusting for age, BMI, alcohol, and energy intake.
Peacock et al.
USA [41] 1999 - 7731/1577
Prospective
cohort - 6 years
Significant trend for the association of serum magnesium and
incident hypertension in women, after adjustment for age, race,
and other risk factors (p trend = 0.01) but not in men
(p trend = 0.16). No association between dietary magnesium
intake and incident hypertension.
Townsend et al.







Similar intakes of magnesium and other minerals in hypertensive
and non-hypertensive participants in both surveys. The pattern of
significantly lower mineral intake (potassium + calcium +
magnesium) emerged as unique to persons with isolated systolic
hypertension in both waves.
He et al. USA [39] 2006 - 4637/608 MS Prospectivecohort - 15 years
Magnesium intake was inversely associated with incidence of
metabolic syndrome after adjustment for major lifestyle and
dietary variables and baseline status of each component of the
metabolic syndrome. The inverse associations were not modified
by gender and race. Magnesium intake was also inversely related
with individual component of the metabolic syndrome.
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USA [40] 2006 - 28,349/8544
Prospective
cohort - 9.8 years
Among women, magnesium intake was inversely associated with
the risk of hypertension (p for trend < 0.0001 of magnesium
quintiles). This inverse association was attenuated but remained
significant after further adjustment for known risk factors
(p for trend = 0.03). Similar associations were observed for
women who never smoked and reported no history of high
cholesterol or diabetes at baseline.









Apparent dose-dependent effect of magnesium on BP,
with reductions of 4.3 mm Hg in systolic BP and of 2.3 mm Hg in
diastolic BP for each 10 mmol/d increase in magnesium dose.
Limiting the analysis to the 14 trials in hypertensives, for each
10 mmol/d of magnesium SBP was reduced by 3.3 mm Hg and
DBP by 2.3 mm Hg.
Dickinson et al.






On average, people receiving magnesium achieved slightly but
significantly lower DBP (mean difference: −2.2 mmHg).
Poor quality and heterogeneity of the trials. None of the studies
reported any serious side effects.
Kass et al.






Small but significant reduction in SBP of 3–4 mm Hg and DBP of
2–3 mm Hg, with greater increased in trials with crossover design
and magnesium dose >370 mg/d.
Rosanoff et al.






Significant mean reduction in SBP (mean −18.7 mmHg) and DBP
(mean −10.9 mmHg) in hypertensives on continuous
anti-hypertensive medication for at least six months, with no more
than a two-week washout, and mean starting SPB > 155 mmHg.
Zhang et al. USA,
China, Canada,
Japan [23]





Significant reduction in SBP (mean −2.0 mmHg) and DBP (mean
−1.78 mmHg) accompanied by 0.05 mmol/L rise in serum
magnesium vs. placebo. Greater BP reduction found in trials with
high quality or low dropout rate.
Dibaba et al.





Significant decrease in BP: mean reduction of 4.18 mm Hg in SBP
and 2.27 mm Hg in DBP in participants with insulin resistance,
prediabetes, or other noncommunicable chronic diseases.
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Significant reduction in SBP (weighted mean
difference = −3.056 mmHg) with greater beneficial effect in
diabetic patients with hypomagnesaemia. High heterogeneity of
the trials. In meta-regression, elemental magnesium dose was
inversely DBP (p < 0.001).








Inverse association between dietary magnesium intake and the
risk of hypertension. A 100 mg/d increment in magnesium intake
was associated with a 5% reduction in the risk of hypertension.
The association of serum magnesium concentration with the risk
of hypertension was marginally significant.
Wu et al. China,









Comparing highest vs. lowest category of circulating magnesium
concentration, the pooled RR was 0.91 (95% CI 0.80, 1.02) for
incident hypertension. Every 0.1 mmol/L increment in circulating
magnesium levels was associated with 4% (RR 0.96; 95% CI: 0.94,
0.99) reduction in hypertension incidence.
Ikbal et al.
Austria [25] 2019
8 (5 of RCTs, 3 of
observational
studies)








The summary showed SBP reductions in the range of
−0.2 and −18.7 mmHg, and DBP reductions between −0.3 and
−10.9 mmHg. The meta-analysis [227] showing the largest effect,
included a small sample of treated hypertensive patients,
which probably responded highly to magnesium. When omitting
this meta-analysis, the BP lowering effects of magnesium were
attenuated to a low to moderate level. Observational studies
showed a lower risk for hypertension with increasing magnesium























High class evidence for the association of diastolic blood pressure
and magnesium in intervention studies with magnesium
supplementation vs. placebo and moderate class evidence for
systolic blood pressure. Large heterogeneity found for this
outcome. The evidence was suggestive for the association of a
higher dietary magnesium intake with a lower risk of stroke in
observational studies.
BMI: body mass index; BP: blood pressure; CI: confidence interval; d: day; DBP: diastolic blood pressure; HTN: hypertension; MS: metabolic syndrome; RR: relative risk; SBP: systolic blood pressure; wks: weeks.
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6. Available Evidence of the Effects of Dietary and Supplemental Magnesium
on Hypertension
The role of magnesium as a therapy for hypertension in young and older adults,
although first reported over 90 years ago for malignant hypertension and pre-eclamptic
pregnancies [5], remains not completely defined. It is noteworthy that the use of intra-
venous magnesium sulfate in pregnancy-associated hypertension and especially in the
prevention and treatment of seizures and PRES in eclampsia is well-established. This is
based on evidence of beneficial effects in RCTs like the Magpie trial [229] and recommended
in current guidelines [230–232], which prospects its validity in the third millennium after
practically one hundred years of use. It should be noted that very high doses are used
in pre-eclampsia and eclampsia and that the collateral effects are minimal considering
that pregnant women are patients in whom particular caution is warranted due to the
eventual consequences for both the mother and the newborn. Older hypertensive adults
are frequently frail persons with multiple comorbidities who could potentially benefit from
magnesium treatment.
Following the first use in 1925, magnesium continued to be utilized in hypertension
associated with eclampsia, acute nephritis, and various vascular disorders, as testified
by an article from 1942 including 40 cases with variable results [233], which discouraged
further studies and recommendations of a regular use at that time. Results from different
small trials remained non-homogeneous later on. Subsequent epidemiologic cross-sectional
studies in the 1980′s and 1990′s suggested an inverse relationship between magnesium
dietary intake and hypertension [33–35,234]. Straightforward recommendations were not
possible upon cross-sectional studies, but the results suggested that foods rich in mag-
nesium, such as vegetables, nuts, legumes, and whole grains may be protective against
hypertension. The heterogeneous results of magnesium supplementation on the risk of
hypertension, with some positive and some negative results, gave rise to a 2006 Cochrane
review and meta-analysis suggesting that there was not yet enough information to recom-
mend a wide use of magnesium in hypertension despite a small statistical reduction in
diastolic blood pressure [226].
Currently, in addition to the former cross-sectional studies mentioned above [33–35,234],
there is convincing evidence from prospective studies of an inverse relationship of di-
etary magnesium intake and of magnesium supplementation with the risk of incident
hypertension [36–40], confirming a protective effect of the ion. There are few studies
with non-optimal designs, two cross-sectional and one longitudinal, reporting negative
or inconclusive results: one cross-sectional study from South Africa including a multi-
ethnic heterogeneous population of 325 participants was inconclusive for a relationship
between magnesium intake and blood pressure [42]; a longitudinal analysis of data from
the Atherosclerosis Risk in Communities Study showed a significant inverse association
of serum magnesium concentrations with incident hypertension in women that did not
reach statistical significance in men (although the trend confirmed an inverse relationship),
and no association between dietary magnesium intake and incident hypertension [41];
a cross-sectional analysis in two waves of data from the NHANES III and NHANES
IV reported similar intakes of magnesium and other minerals in hypertensive and non-
hypertensive participants in both surveys. However, the pattern of significantly lower
mineral intake (potassium + calcium + magnesium) emerged as unique to persons with
isolated systolic hypertension in both NHANES III and NHANES IV [43].
Three meta-analyses of RCTs found that participants receiving magnesium supple-
mentation had a significant reduction in blood pressure values vs. controls [22,23,44].
The meta-analysis by Dibaba et al. included 11 RCTs and 543 participants followed up for
periods ranging from one to six months. The daily dose of elemental magnesium used in
the trials ranged from 365 to 450 mg. The pooled results indicated that magnesium sup-
plementation had a significantly greater reduction in systolic and diastolic blood pressure
when compared to controls without supplementation in patients with insulin resistance,
prediabetes, or other non-communicable chronic diseases [22]. A second meta-analysis by
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Zhang et al. included 34 RCTs and 2028 participants with a median dose of magnesium
supplementation of 368 mg/d for a median duration of 3 months. The authors reported a
significant reduction in systolic and diastolic blood pressure, accompanied with an eleva-
tion of serum magnesium concentrations when compared to placebo. One month of therapy
with 300 mg/d was sufficient to elevate serum magnesium and reduce blood pressure
according to restricted cubic spline curve analyses. A greater reduction of blood pressure
were found in trials with high quality or low dropout rate, but residual heterogeneity
was also found when these factors were considered [23]. A third meta-analysis of RCTs
by Verma et al. evaluating the effect of magnesium supplementation on cardiovascular
risk factors (including hypertension) in diabetic and nondiabetic participants found a
favorable effect of magnesium supplementation on systolic blood pressure, together with
reductions in fasting plasma glucose, high-density lipoprotein and low-density lipopro-
tein cholesterol and triglycerides, effects that were stronger in diabetic participants with
hypomagnesemia. The meta-analysis included 28 RCTs, but only four were conducted in
hypertensive participants [44].
Former meta-analyses suggested benefit with less prominent but still positive effects,
possibly due to heterogeneity of the studies included in the analyses [24,45]. A meta-
analysis by Kass et al., included 22 RCTs and 1173 participants with a range of follow-up
between 3 and 24 weeks, and a daily dose of elemental magnesium ranging from 120 to 973
(mean dose of 410 mg/d). Although not all trials showed a significant blood pressure reduc-
tion, combining them there was a significant decrease in systolic (minus 3–4 mm Hg) and
diastolic (minus 2–3 mm Hg) blood pressure, which was stronger for trials with crossover
designed and doses higher than 370 mg per day. Overall, the size of the effect increased in
parallel with the dose increment. The authors concluded that magnesium supplementa-
tion had a small but significant reducing effect on blood pressure, which warranted the
implementation of larger RCTs [24]. Another meta-analysis by Jee et al., including 20 RCTs,
most of them very small, with a total 1220 participants and a daily dose of magnesium
supplementation ranging from 241 to 964 mg (median dose 371.1 mg/d), resulted in a
small but significant effect for systolic blood pressure; diastolic blood pressure was also
reduced without reaching the statistical significance. Nevertheless, there was an apparent
dose-dependent effect of magnesium on blood pressure with reductions of 4.3 mm Hg in
systolic blood pressure and of 2.3 mm Hg in diastolic blood pressure for each 241 mg/day
increment in magnesium dose. Because the trials included were heterogeneous, the au-
thors suggested that adequately powered trials with sufficiently high doses of magnesium
supplements were needed to confirm their results [45].
Another meta-analysis with a different design by Rosanoff et al., examining 44 studies
that were sorted according to hypertension status, magnesium dose and anti-hypertensive
medication usage, showed that some studies reported significant lowering of blood pres-
sure with magnesium supplementation, while others did not. Therefore, they performed
analyses of a uniform subset of seven studies from the original studies identified involv-
ing 135 hypertensive participants on anti-hypertensive medication continuously for at
least six months, with no more than a two-week washout, and with a mean starting
systolic blood pressure higher than 155 mm Hg. In this subset of studies, the authors
showed significant blood pressure reductions with magnesium supplementation (mean
reductions in mm Hg of 18.7 mm Hg for systolic blood pressure and 10.9 mm Hg for
diastolic blood pressure). The rest of the original trials, not fulfilling the characteristics
described above, showed heterogeneous results, probably including high- and low- or
non-responder participants combined [227]. The authors argued that the modest results
reporter in former meta-analyses by Kass et al. [24], Jee et al. [45], and the Cochrane review
by Dickinson et al. [226], were probably due to the fact that they blended dissimilar studies,
which contributed to underestimate the potential of magnesium in hypertension in some
(but not all) participants. Un umbrella review of systematic reviews and meta-analyses of
observational and interventions studies from our group found a high-class evidence for
the association of diastolic blood pressure and magnesium in intervention studies with
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magnesium supplementation vs. placebo and moderate class evidence for systolic blood
pressure. The evidence was suggestive for the association of a higher dietary magnesium
intake with a lower risk of stroke in observational studies [31].
Regarding dietary magnesium intake, a systematic review and meta-analysis of cohort
prospective studies assessed the association of dietary magnesium intake and serum
magnesium with incident hypertension. The meta-analysis included nine studies (6 on
dietary magnesium, 2 on serum magnesium, and 1 in both) of ten cohorts and 20,119 cases
of hypertension in 180,566 participates. Results showed a significant inverse relationship
between dietary magnesium intake and the risk of incident hypertension when comparing
the highest intake group with the lowest. For each 100 mg/day increment in magnesium
intake there was a 5% lower risk of incident hypertension. The relation between the
serum magnesium levels and the risk of hypertension was only marginally significant [21].
Dietary patterns reported to significantly reduce blood pressure in hypertensive and pre-
hypertensive patients include Dietary Approaches to Stop Hypertension (DASH) and
Mediterranean diet [235], both rich in foods such as vegetables, nuts, whole cereals and
legumes—optimal dietary sources of magnesium. Interestingly, DASH, ranked as the most
effective dietary model in reducing blood pressure [235], emphasizes the high content of
minerals, including magnesium.
Concerning blood magnesium levels, a meta-analysis of cohort studies evaluated the
association of circulating magnesium concentrations with the incidence of coronary heart
disease, hypertension, and type 2 diabetes, including 11 studies (3 with results on hyper-
tension, 14,876 participants with 3149 cases and mean 6.7-year follow-up). The pooled
relative risk of incident hypertension was 0.91 (95% confidence intervals 0.80, 1.02; NS)
comparing the highest to the lowest category of circulating magnesium concentration.
However, the trend was significant with every 0.1 mmol/L increment in circulating mag-
nesium being associated with a 4% reduction in hypertension incidence [228]. A recent
review examining meta-analyses on the effects of electrolytes on hypertension including
32 meta-analyses showed that magnesium had the greatest blood pressure lowering effect
followed by potassium and by sodium/salt reduction [25]. Table 4 summarizes the results
from prospective studies and meta-analyses of trials or cohort studies on the association of
magnesium and hypertension included in the review.
In summary, almost all (five out of seven) prospective observational studies exploring
the association of dietary magnesium intake with incident hypertension reported significant
inverse associations, sometimes varying among men and women. Only one of these studies
reported data on serum magnesium showing a significant inverse association of serum
magnesium with incident hypertension in women but not in men. All seven meta-analyses
on RCTs testing the effects of magnesium supplementation on blood pressure reported
significant blood pressure lowering effects. A meta-analysis of observational studies
evaluating the association of dietary magnesium with the risk of hypertension reported
a significant inverse association with each 100 mg/d increment of magnesium intake
being associated with a 5% reduction in hypertension risk. A meta-analysis of serum
magnesium concentrations with the risk of hypertension reported marginally significant
effects. A summary of meta-analyses and an umbrella review reported generally positive
effects as well. Nevertheless, it should be taken into account that all meta-analyses indicated
the presence of large heterogeneity among the hitherto available trials.
7. Conclusions
Over the past decades, there has been an outstanding amount of experimental,
epidemiological, and clinical evidence showing a close relationship between magnesium
deficit and high blood pressure. As shown in Figure 2, the multiple effects of magnesium
on key mechanisms linked to the generation of arterial hypertension and its complications
make this link strongly plausible and help to explain the bulk of evidence supporting a
protective effect of magnesium against hypertension.
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Magnesium has been used empirically for a century to treat severe hypertensive con-
ditions, and in some cases, the most severe, such as pre-eclampsia, eclampsia-associated
seizures and PRES, continues to be included in the guidelines of the third millennium,
a century after having started its use. Hypertension is a complex condition in which various
actors and mechanisms combine, resulting in cardiovascular and cerebrovascular compli-
cations that today represent the most frequent causes of mortality, morbidity, disability,
and health expenses worldwide. This condition increases sharply with advancing age,
hence older persons are those most affected by the negative consequences of hypertension.
They are also more frequently at risk of magnesium deficiency by multiple mechanisms
(Table 3), which may, at least in part, explain the higher frequency of hypertension and
its long-term complications. Thus, older people have concurrently a higher risk for these
two complex conditions. Moreover, the frequent use of diuretics as a therapy for hyper-
tension and for one of its long-term complications, heart failure, can even worsen the
magnesium deficiency.
Notwithstanding the convincing evidence that validates the possible key role of mag-
nesium in hypertension, it is important to keep in mind that magnesium alone is not enough
for hypertension prevention and/or treatment purposes. As mentioned, hypertension
involves complex interactions among numerous endogenous and environmental factors;
hence, the idea that it can be prevented or treated with a “magic bullet” is overstated and
senseless. Furthermore, the main sources of dietary magnesium, i.e., vegetables, legumes,
whole cereal , and nuts, contain also other components with health benefits, such as vita-
mins, other miner l and micronutrients, fiber, and phytochemicals with anti-inflammatory
and antioxidant ffects. At present, nutri ion research emphasizes the impact of foods and
nutrients combin tions, as opposed to th reductionist approa based on single nutrients
or f , which was extensively con idered in the past whe diseases due to specific
nutritional deficiencie ere described and prevailing. Nev rtheless, studie a j sted
for multiple confounders have still r ported ndependent associations of magnesium and
hypert nsi n. Moreover, at a popul tion level, magnesium may be a marker of other signif-
icant risk factors for hypertension and f adherence to a healthy diet. Other non-dietary
components of a healthy lifestyle are generally associated with a healthy diet [236]. Hence,
dietary magnesium intake may be a marker of a healthy diet and lifestyle and may not
only reflect the biological effect of an isolated healthy nutritional component.
The evidence for a beneficial effect of magnesium on hypertension risk emphasizes
the importance of broadly encouraging the consumption of foods such as vegetables,
nuts, whole cereals and legumes, optimal dietary sources of magnesium, avoiding pro-
cessed foods, which are very poor in magnesium and lack other fundamental nutrients
as well, in order to prevent hypertension. In some cases when diet is not enough to main-
tain an adequate magnesium status, magnesium supplementation may be of benefit and
has been shown to be well tolerated.
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